Proteasome inhibitor-based therapy for antibody-mediated rejection
Proteasome inhibitor-based therapy for antibody-mediated rejection
About this item
Full title
Author / Creator
Publisher
Basingstoke: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
Basingstoke: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
The development of donor-specific anti-human leukocyte antigen antibodies (DSAs) following renal transplantation significantly reduces long-term renal graft function and survival. The traditional therapies for antibody-mediated rejection (AMR) have provided inconsistent results and transient effects that may be due to a failure to deplete mature an...
Alternative Titles
Full title
Proteasome inhibitor-based therapy for antibody-mediated rejection
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1020855001
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1020855001
Other Identifiers
ISSN
0085-2538
E-ISSN
1523-1755
DOI
10.1038/ki.2011.502
